| HOME >> MEDICINE >> TECHNOLOGY |
Table 41: Competitive Comparison of Target Strategies of Antibody Based Lymphoma Drugs 617
Table 42: Pursued Target Strategies of Antibody Based Lymphoma Drugs 619
Table 43: Overview of the Competitive Landscape of Nucleic Acid Based Lymphoma Drugs 623
Table 44: Competitive Comparison of Target Strategies of Nucleic Acid Based Lymphoma Drugs 624
Table 45: Pursued Target Strategies of Nucleic Acid Based Lymphoma Drugs 624
Table 46: Potential Forms of Cell Therapy 625
Table 47: Vectors in Gene Therapy 626
Table 48: Overview of the Competitive Landscape of Cell Therapy Based Lymphoma Drugs 626
Table 49: Pursued Target Strategies of Cell Therapy Based Lymphoma Drugs 626
Table 50: Overview of the Competitive Landscape of Gene Therapy Based Lymphoma Drugs 627
Table 51: Pursued Target Strategies of Gene Therapy Based Lymphoma Drugs 628
Table 52:Overview of the Competitive Landscape of Reformulated Lymphoma Drugs 629
Table 53: Competitive Comparison of Target Strategies of Reformulated Lymphoma Drugs 630
Table 54: Pursued Target Strategies of Reformulated Lymphoma Drugs 630
Table 55: Compound Strategies based on Sub-Cellular Localization of Lymphoma Drug Targets 632
Table 56 Competitive Summary by Subindication of Lymphoma Drugs 637
Table 57: Target Strategy Development Profiles of Drugs for the Treatment of B-cell Lymphoma Drugs 638
Table 58: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 640
Table 59: Target Strategy Development Profiles of Drugs for the Treatment of Hodgkin's Lymphoma 641
Table 60: The Competition through Close Mechanistic Approximation between Hodgkin's Lymphoma Drugs 643
Table 61: Target Strategy Development Profiles of Drugs for the Treatment of non-Hodgkin's Lymphoma 644
Table 62
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |